Amgen slides 10% amid olpasiran read-through concerns (AMGN:NASDAQ)
· seekingalpha.com
Amgen stock fell 10% after Novartis’ pelacarsen Phase 3 failure raised olpasiran concerns.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...